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ABSTRACT
The complexity of chronic graft-versus-host disease (GVHD) and the lack of established research methods have
made it difficult to design, conduct, and analyze clinical trials involving subjects with this disease, even when
promising treatment options are available. This consensus document was developed to offer an approach for
overcoming these obstacles. Clinical trials in chronic GVHD should adhere to principles of good trial design and
practice. Inclusion and exclusion criteria should allow as many subjects to participate as possible without compro-
mising the interpretation of results. Pre-enrollment assessment of chronic GVHD characteristics should be
standardized. The protocol should provide clear guidance about administration of study medication and other
interventions. Methods of assessing response should be defined and validated in advance. Efficacy endpoints should
be selected to reflect clinical benefit. Expert biostatistical support is needed to ensure the validity and reliability of
trial results. The use of consistent standards in clinical trial designs to evaluate agents that have activity in
pathogenic pathways could facilitate advances in the treatment of chronic GVHD.
© 2006 American Society for Blood and Marrow Transplantation
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Previous studies have provided a good understand-
ng of risk factors for development of chronic graft-
ersus-host disease (GVHD) and risk factors for mortal- r
B&MTty among patients with newly diagnosed chronic
VHD. Advances in supportive care have decreased
orbidity, but survival for patients with chronic GVHD
as not changed since the mid-1980s. Five-year survival
ates for patients with newly diagnosed “standard-risk”
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4hronic GVHD (platelet count100 000/L and onset
ithout previous acute GVHD or after resolution of
revious acute GVHD) have remained at approximately
0%, and 5-year survival rates for those with “high-risk”
hronic GVHD (platelet count 100 000/L or pro-
ressive onset from acute GVHD) have remained at
0-50% [1,2]. In aggregate, only 50% of patients with
hronic GVHD are able to discontinue immunosuppres-
ive treatment within 5 years after the diagnosis, and
0% require continued treatment beyond 5 years. The
emaining 40% die or develop recurrent malignancy
efore chronic GVHD resolves [2].
URPOSE OF THIS DOCUMENT
A variety of inherent challenges must be consid-
red in designing a clinical trial of treatment for
hronic GVHD. The numbers of patients with
hronic GVHD in any single institution are generally
ot sufﬁcient for studies intended to establish safety
nd efﬁcacy for investigational products in a reason-
ble period. Studies that enroll patients at several
nstitutions are more likely to meet accrual targets and
rovide the necessary data to analyze outcomes in a
obust manner. A major challenge is to coordinate and
lign the practices for the purpose of an efﬁcient trial
esign and unbiased analysis at institutions that have
volved divergent standards based on their own re-
ources and experience.
The goal of this working group is to recommend
pproaches and deﬁnitions to ensure consistent and
nterpretable results of clinical studies designed to
ssess interventions for treatment of chronic GVHD.
t is not a goal of this working group to recommend
tandards of care for clinical practice. Considerations
or trials intended as formal demonstration of safety
nd efﬁcacy are noted where applicable. Prevention
rials and observational studies will not be extensively
ddressed in this document.
In designing any clinical trial, 3 critically impor-
ant questions must be considered: (1) Who will be
nrolled in the trial? (2) How will subjects be treated?
3) How will results be evaluated? We concentrate our
ecommendations on areas where consensus among
embers could be achieved, and where we believe that
well-accepted standard would signiﬁcantly enhance
he conduct and consistency of clinical trials to eval-
ate prevention and treatment of chronic GVHD.
hese recommendations will be modiﬁed with further
nput from the transplantation community and will be
pdated as new information about chronic GVHD
ecomes available. An appendix, Consensus Deﬁni-
ions and Glossary—2006, deﬁnes the boldface terms
nd represents opinions of the working group or are
erms that might be unfamiliar to readers. n
92UMMARY OF RECOMMENDATIONS
. Inclusion and exclusion criteria should encompass as
many people with chronic GVHD as possible without
compromising the ability to interpret results of the study.
. Baseline evaluations should document the need for ther-
apy, identify prognostic characteristics, and speciﬁcally
characterize the condition of subjects at the time of
enrollment, so that results of therapy can be interpreted.
. Within reason, the study protocol should specify or pro-
vide guidance regarding the dosing and dose adjustment
of all immunosuppressive medications, including the
study drug. Reasons for deviations should be noted in
case-report forms.
. Case-report forms should be calendar driven by the
protocol to provide assessment of chronic GVHD and
adverse events at regular intervals. Patient-reported
measures should be incorporated whenever feasible.
Standardized and clinically validated measurements
should be used.
. There is urgent need for validation of consensus response
measurements. To this end, enrollment in observational
studies and clinical trials that test prospective markers
and criteria should be encouraged.
. Primary and secondary endpoints should be selected for
their ability to demonstrate clinical beneﬁt, which can be
a prolongation of survival or an improvement in the
way a patient feels or functions. Endpoints should ac-
count for competing outcomes such as death or recurrent
malignancy. Composite endpoints may be required in
some speciﬁc protocols.
. Biostatistical analysis should incorporate considerations
of competing events and concomitant therapy, appropri-
ate power calculations, interim analyses, sensitivity
analysis, and missing measurements.
TUDY POPULATIONS
eneral Considerations
The study design should have eligibility criteria,
nd pre-study evaluations should document the diag-
osis of chronic GVHD, account for the probable
isk-beneﬁt ratio to individual participants, and ensure
nterpretability of the ultimate results. The diagnosis
f chronic GVHD should be established according to
he deﬁnitions provided in the diagnosis and staging
ocument [3]. Whenever feasible, the diagnosis of
hronic GVHD should be documented by photogra-
hy or conﬁrmed by tissue biopsy before patients are
nrolled in treatment trials [4]. Information from
ell-documented baseline evaluations can be used not
nly to demonstrate eligibility for enrollment but
ight also be used for future assessment of previously
nidentiﬁed risk factors.
In treatment trials, inclusion criteria depend pri-
arily on whether the population of interest has
ewly diagnosed chronic GVHD requiring “pri-
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Design of Clinical Trials in Chronic GVHD
Bary” therapy or more advanced chronic GVHD
hat has already not improved or has recurred after
rimary therapy, thus requiring “secondary” treat-
ent. Although chronic GVHD occurs in 30-60% of
urvivors after hematopoietic cell transplantation
HCT), the heterogeneity of the syndrome makes it
ifﬁcult to accrue a homogeneous cohort in any study.
nclusion and exclusion criteria must balance the need
or a representative selection of subjects (arguing that
large proportion of people with chronic GVHD
hould be eligible) versus the need for clear interpre-
ation (arguing that the study population should be as
omogeneous as possible). In general, phase III trials
hould be more inclusive, whereas phase II trials may
eed to be more restrictive to facilitate the use of early
nd intermediate endpoints. Inclusion of children is
ncouraged in phase II and III studies and may require
ssessments of additional endpoints, such as growth
nd development, which are relevant to this popula-
ion. Studies limited to enrollment of children may
lso be feasible through the participation of pediatric-
riented cooperative groups.
nclusion Criteria in Clinical Trials Testing Topical
r Systemic Agents as Primary Therapy
Current criteria deﬁne the diagnosis and scoring
f chronic GVHD more precisely than previously and
nclude considerations of symptom severity, func-
ional impairment, and prognosis [3].
In general, systemic immunosuppressive treat-
ent is not needed for patients who have chronic
VHD with only mild abnormalities involving only 1
r perhaps 2 sites with no symptoms or only mild
ymptoms and no functional impairment and no char-
cteristics that portend a poor prognosis. These pa-
ients may be suitable for enrollment in clinical trials
o evaluate topical agents [3].
Systemic treatment is needed for patients who
ave chronic GVHD that causes more severe abnor-
alities or complications such as fasciitis, contrac-
ures, or pulmonary involvement and for patients with
linical characteristics indicating a poor prognosis.
hese patients may be suitable for enrollment in clin-
cal trials to evaluate systemic agents. Patients with
ore severe abnormalities or complications may also
e suitable for enrollment in clinical trials to evaluate
opical agents as long as participation in the trial
ermits systemic treatment and accounts for its ef-
ects.
nclusion Criteria in Clinical Trials of Secondary
herapy
Criteria for secondary treatment should be
learly delineated in the protocol. Secondary treat-
ent is indicated when primary therapy has failed asndicated by progression of chronic GVHD signs and f
B&MTymptoms during therapy. In some circumstances,
econdary therapy may also be instituted for persistent
teroid-dependent chronic GVHD. Steroid-intol-
rant patients with steroid-responsive chronic
VHD can also be enrolled in clinical trials of sec-
ndary therapy, provided that steroid intolerance is
trictly deﬁned. Inclusion of steroid-intolerant pa-
ients would not pose a problem when the primary
ndpoint is safety. Stratiﬁcation would be needed in a
andomized trial in which the primary endpoint is
fﬁcacy, because the response rate among steroid-
ntolerant patients could be higher than that among
hose with steroid-refractory or steroid-dependent
hronic GVHD.
A key issue for clinical trials testing secondary
herapy is whether and how to limit enrollment of
atients with far advanced chronic GVHD that has
roduced irreversible damage or has proved resistant
o more than a single previous treatment. Responsive-
ess of the disease will likely depend on the extent of
isease activity as opposed to irreversible damage.
ven if the study intervention inhibits disease activity,
linical beneﬁt would not be evident if most manifes-
ations represent irreversible damage that has already
ccumulated during the previous course of the disease.
Enrollment of patients with far advanced chronic
VHD might be appropriate when the primary end-
oint is related to safety and tolerance or to efﬁcacy as
easured by arrested progression of the disease, but a
ack of improvement during treatment would be dif-
cult to interpret in patients with irreversible contrac-
ures, bronchiolitis obliterans, or sicca syndrome, if
hese are the only manifestations of chronic GVHD.
atients with irreversible damage as the only manifes-
ation of chronic GVHD should be excluded from
rials designed to measure improvement in chronic
VHD, although it may be appropriate to include
hese patients in studies in which the primary end-
oint is survival, prevention of chronic GVHD pro-
ression, palliation of disease manifestations that are
rdinarily considered irreversible (eg, through the use
f anti-ﬁbrotic medications), or reduction in the dose
f steroid treatment. Patients who have reversible and
rreversible manifestations of chronic GVHD can be
nrolled in trials with endpoints related to clinical
mprovement, but the trial design should specify how
reviously established irreversible damage will be as-
essed. Organs or sites affected by irreversible damage
ould be excluded for purposes of evaluating improve-
ent, but they should be included for purposes of
valuating possible progression of the disease. Clinical
rials for secondary treatment of chronic GVHD
ould beneﬁt enormously from the availability of
arkers indicating disease activity as distinguishedrom damage.
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4xclusion Criteria
In clinical trials of treatment for chronic GVHD,
xclusion criteria generally address the presence of (1)
ncontrolled infection at the time of enrollment, (2)
ontraindications to administration of the study inter-
ention or known inability of the patient to tolerate
he study intervention, and (3) complications such as
ecurrent or progressive malignancy that might af-
ect the study endpoints or temper the effort to con-
rol chronic GVHD. Other typical exclusion criteria
nclude pregnancy or breast-feeding, an unwillingness
o comply with any critical components of study treat-
ent or response evaluation, or short duration of
nticipated survival due to other comorbidities. Com-
lications such as fasciitis, contractures, and pulmo-
ary involvement may evolve into fixed, irreversible
eficits that do not improve during immunosuppres-
ive treatment. Patients may be excluded from enroll-
ent in certain clinical trials if these deﬁcits are truly
rreversible and if their presence would interfere with
he assessment of efﬁcacy, but they could be enrolled
n a trial with survival as the endpoint if stabilization
f the irreversible deﬁcit would be expected to pro-
ong survival.
ixed Acute and Chronic GVHD
A recognition of overlap syndromes in which
hronic GVHD occurs with manifestations typical of
cute GVHD has increased recently. Inclusion of pa-
ients with such overlap syndromes may complicate
he interpretation of phase II trials because the re-
ponse of individual organs may depend on whether
cute or chronic GVHD is predominant. Unambigu-
us response criteria are needed for each organ if
atients with overlap syndromes are included in phase
I trials in which shorter-term clinical response is the
rimary endpoint. Patients with overlap syndromes
an be included in phase III trials in which resolution
f GVHD, discontinuation of therapy, or survival is a
omponent of the primary endpoint. Stratiﬁcation
ay be needed to account for different outcomes
ccording to the presence or absence of acute GVHD.
onsiderations for Drug Development
Conventionally, new agents have been tested for
afety and for initial assessment of efﬁcacy among
atients with steroid-refractory GVHD, under the
remise that only patients at very high risk of poor
utcomes should be subjected to the unknown risks of
new agent. This approach, however, poses several
ractical problems. Patients with steroid-refractory
VHD have highly heterogeneous disease manifesta-
ions and risk factors, making it difﬁcult to evaluate
fﬁcacy except through evaluations of change over
ime for individual patients. The number of patients
ith steroid-refractory GVHD is smaller than the t
94umber with newly diagnosed GVHD. In addition,
teroid-refractory GVHD is less likely than newly
iagnosed GVHD to respond to therapy.
Because patients may be reluctant to enroll in
lacebo-controlled trials for steroid-refractory
VHD, protocols would beneﬁt from designs that
ffer all patients some chance of beneﬁt from partic-
pation in the study. Comparative trials are difﬁcult
ecause no agents have been approved for treatment
f steroid-refractory GVHD. A comparative trial of
n unapproved agent against best supportive care
ould be considered, although there is currently no
tandard for deﬁning best supportive care. A compar-
tive trial of an agent already approved for other
ndications may be hampered by the availability of the
gent for off-label use outside the context of a study.
he use of a crossover design might improve enroll-
ent in comparative studies for treatment of steroid-
efractory chronic GVHD. If a crossover design is
sed, the criteria for changing therapy should be ex-
licit and unambiguous, and the primary outcome
ariable should be assessed before the crossover.
If the phase II experience in patients with steroid-
efractory GVHD is encouraging, a pivotal phase III
ontrolled study may be necessary as a formal dem-
nstration of efﬁcacy. Because the number of patients
ith newly diagnosed chronic GVHD is larger than
he number with steroid-refractory GVHD, and be-
ause response may be easier to assess in patients with
ewly diagnosed chronic GVHD, a phase III study
ould enroll patients with newly diagnosed GVHD,
here a new agent could be tested as an “add-on” to
standard” ﬁrst-line therapy. If a phase III study in
atients with newly diagnosed chronic GVHD is nec-
ssary under circumstances in which phase II results
re not available in the same population, a decision
ust be made whether to forge ahead with the phase
II study or whether to conduct a separate phase II
tudy in patients with newly diagnosed chronic
VHD before undertaking a phase III study. This
ecision will depend on whether the safety and efﬁ-
acy experiences from previous studies are adequate to
ormulate a reasonable expectation of risk and a pre-
iminary estimate of the effect size to assess the po-
ential for beneﬁt in subjects to be enrolled in the
hase III study.
Alternatively, a “window” approach could be used
n phase II studies in which a new agent is given for a
imited time before beginning standard therapy for
ewly diagnosed chronic GVHD. A window study can
e used most appropriately with interventions that can
roduce rapid improvement. Positive results with a
indow approach could lead to subsequent phase II
tudies to assess the response rate and collect other
harmacodynamic or pharmacokinetic measures dur-
ng longer-term administration of the agent. Alterna-
ively, phase III studies could be carried out to com-
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Design of Clinical Trials in Chronic GVHD
Bare the investigational agent designed against
tandard therapy in a newly diagnosed population.
REATMENT METHODS
uidance Regarding the Management of Chronic
VHD
The level of guidance regarding the management
f chronic GVHD in protocols should be appropriate
o the lowest level of expertise among the providers
ho are likely to participate in the study. In the
nited States, most allogeneic HCT is performed in
ertiary care centers. However, the median onset of
hronic GVHD occurs at 4-6 months from HCT,
fter many patients have returned to the care of their
eferring physicians. These specialists typically have
xpertise in oncology or hematology but not in the
iagnosis and management of chronic GVHD. If it is
nticipated that referring hematologists and oncolo-
ists will be involved in study conduct or follow-up,
anagement guidelines should be targeted to their
evel of expertise. Speciﬁc training toward study goals
nd proper procedures for all personnel should be
onsidered as an important tool to ensure quality and
onsistency.
dministration of a Study Medication or
ntervention
Protocols for treatment of chronic GVHD must
eﬁne appropriate guidelines for administration of the
tudy medication or intervention, including the initial
osage, monitoring of blood levels, any decreases in
ose or frequency of administration indicated because
f toxicity, and any tapering of doses or frequency of
dministration at the end of treatment. Clinical trials
nvolving treatment for chronic GVHD have the ad-
itional complexity that the study medication or in-
ervention is frequently used in conjunction with
ther immunosuppressive treatments or interventions
hat increase the potential for drug interactions. The
eed for or use of additional agents could be consid-
red as secondary endpoints during a planned taper of
mmunosuppressive treatment, but blinding would be
eeded for optimal interpretation of these endpoints.
dministration of Glucocorticoids
“Standard” steroid therapy currently represents
well-established mainstay of initial treatment for
hronic GVHD. Although the evaluation of a new
reatment for chronic GVHD might ideally be carried
ut under stable conditions in which all other compo-
ents of treatment are held constant, this ideal is very
ifﬁcult to achieve in practice, if only because long-
erm high-dose glucocorticoid treatment causes unac-
eptable morbidity. This circumstance creates a med-
cal and ethical imperative to prescribe the lowest dose b
B&MTf glucocorticoid treatment that effectively controls
VHD manifestations. This means that, if GVHD
mproves during investigational treatment, glucocor-
icoid doses should be decreased accordingly, even
hough the decrease in steroid doses may prolong the
ersistence of GVHD manifestations compared with
utcomes that might have occurred with continued
igh-dose glucocorticoid treatment. However, taper-
ng of steroid doses prompted by clinical improvement
ould mask the full beneﬁt of an effective investiga-
ional agent, and continued administration of high-
ose steroids could mask the absence of beneﬁt from
n ineffective investigational agent.
Protocols should provide guidelines for taper-
ng of glucocorticoid doses and should specify
aily or alternate-day administration. Guidelines
hould indicate the appropriate starting dose and
ny adjustments in glucocorticoids doses, depend-
ng on toxicity and changes in GVHD severity. A
xed starting dose and taper schedule may be ap-
ropriate for clinical trials in which administration
f glucocorticoids is an integral component of the
ntervention being tested and for trials to evaluate
hort-term efﬁcacy of a new regimen. In longer-
erm trials, however, adherence to a ﬁxed schedule
s likely to be impossible because of variation among
ubjects in persistence of chronic GVHD and tol-
rability of glucocorticoid-related side effects. Pro-
ocols should highlight the possibility of adrenal
nsufﬁciency at the end of the glucocorticoid taper
nd should provide guidelines for reinstitution of
lucocorticoid treatment if GVHD recurs after glu-
ocorticoid administration has been discontinued.
dministration of Other Treatments
Protocols should provide guidelines for the ad-
inistration of immunosuppressive medications and
ny other treatments that could affect manifesta-
ions of GVHD and potentially confound the inter-
retation of the study. Information about the ad-
inistration of any such treatments should be
ecorded for analysis at the end of the study (see
ontent of case-report forms below). Study require-
ents must ﬁnd a balance between the physician’s
otential need for ﬂexibility in deviating from a
rescribed course and the study’s need for consis-
ent medical management. This balance becomes
specially difﬁcult in open-label studies and in trials
ith longer-term endpoints that involve physician
udgment regarding decisions to add or withdraw
edications from the immunosuppressive regimen
r to adjust the pace of taper. Use of any medication
hat could potentially affect the course of chronic
VHD or severity of organ manifestations should
e recorded in the case-report forms.
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4ncillary Therapy, Supportive Care, and
revention of Steroid-Related Complications
Protocols should provide guidelines for preven-
ion of opportunistic infection in patients with chronic
VHD [5]. Protocols should also acknowledge that
rgan or site-specific therapies are an important
omponent of symptom management in patients with
hronic GVHD [5]. Allowable site-speciﬁc therapies
hould be speciﬁed in the protocol, and the therapies
sed for patients should be recorded in the case-report
orms. Protocols should remind providers that close
ttention must be paid to complications of glucocor-
icoid treatment and should suggest management
trategies.
ATA COLLECTION
iming of Data Collection
Calendar-driven data collection (eg, every 3 or 6
onths) is strongly recommended for clinical trials of
reatment for chronic GVHD. Insufﬁciently frequent
ssessment could overlook differences in time to re-
ponse between study arms, whereas too frequent as-
essments might make it difﬁcult to detect changes
rom 1 evaluation to the next and would unnecessarily
dd to the resource burden of the study. Calendar-
riven data collection should be supplemented by
vent-driven collection of GVHD-related data at the
ime of treatment success or treatment failure. Col-
ection of adverse event data should also be event
riven.
Longitudinal or time-to-event analysis can be ac-
ommodated by calendar-driven data collection, al-
hough careful planning would be required if treat-
ent involves cycles of different lengths between
tudy arms. For GVHD therapy trials, we strongly
avor real-time collection of prespeciﬁed data from
hysicians and patients during clinic visits. This ap-
roach ensures the capture of detailed and directed
nformation that may be necessary to document re-
ponse assessments [6].
ase-Report Forms
Standardized case-report forms should be used,
ith the level of detail determined by the study goals.
ata collected retrospectively from medical charts in-
ended for clinical care lack details needed to assess
he results of clinical trials. Instead, a checklist form
hould be used routinely for assessment and documen-
ation of chronic GVHD manifestations during clinic
isits. Consistent template-driven documentation at
n appropriate level of detail through the real-time use
f standard assessment forms enables comparisons
ith previous assessments or with the patient’s base-ine condition. If time points for assessment are stan- t
96ardized, then data for all patients in each study arm
an be easily aggregated for analysis.
Three levels of data regarding chronic GVHD
re outlined in the appendix. These levels describe the
mount of detail to be collected, depending on
hether chronic GVHD is a primary, secondary, or
ertiary endpoint in the study. Investigators are often
empted to collect any data element that might possi-
ly be used in an analysis. Over-collection of data adds
o the burden of participation experienced not only by
hysicians but also by subjects. Excessive data collec-
ion can compromise enthusiasm for the trial and
ncrease the probability that critical data elements will
e missed or that inappropriate analysis will occur.
onversely, elimination of unnecessary data collec-
ion, without compromising collection of safety data,
acilitates the conduct of clinical trials.
ontent of Case-Report Forms
Case-report forms for the baseline assessment of
hronic GVHD should collect information regarding
ligibility for enrollment in the trial, manifestations
hat indicate prognosis, and severity of manifestations
n each organ or site potentially affected by the disease
6]. Previously recognized prognostic indicators at the
nset of chronic GVHD include performance status,
ichen planus-like versus sclerotic skin lesions, percent
ody surface affected by rash, diarrhea, weight loss
10%, oral involvement, platelet count, total biliru-
in, progressive onset from previous acute GVHD
ersus onset without previous acute GVHD or after
esolution of previous acute GVHD, and type and
ose of previously administered immunosuppressive
edications [2,7].
At each subsequent calendar-driven assessment
oint, the dose and schedule of the investigational
gent should be recorded together with the reasons
or any dose interruption or reduction, and the assess-
ent of GVHD severity should be repeated together
ith any other necessary endpoint information spec-
ﬁed by the study design. Drug diaries can be used to
dentify the maximum, minimum, or average dose of
he investigational agent during intervals between as-
essment points. The amount of concomitant immu-
osuppressive medications, ancillary therapies, and
upportive care (eg, physical therapy, massage, punctal
lugs) should also be recorded. In trials in which the
lood levels of an investigational medication are not
onitored and adjusted as part of the study, it may
lso be useful to record the administration of speciﬁc
oncomitant medications that might affect the con-
entration of investigational agents in the blood. All
oncomitant medications must be recorded in studies
o be submitted for regulatory review. The informa-
ion from case-report forms of this design can effec-
ively describe not only the initial onset and ﬁnal
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Design of Clinical Trials in Chronic GVHD
Besolution of chronic GVHD but also its severity
cross time.
atient-Reported Outcomes
Information in the case-report form can include
uality of life or functional assessments as reported
y patients. Collection of patient-reported data should
se validated instruments that have been conﬁrmed
n the speciﬁc patient population. Established meth-
ds of instrument administration and scoring should
e used, whenever such instruments and methods are
vailable. Each instrument should deﬁne clinically
eaningful differences that qualify as improvement
r worsening between 2 assessments based on statis-
ical considerations or clinical perceptions. Results
hould report population changes and percentage of
atients with clinically meaningful difference in self-
eported outcomes before and after treatment. We
ncourage the development of instruments to capture
arent or self-reported data from pediatric patients.
eporting of Adverse Events and Serious Adverse
vents
The protocol document should specify a safety-
onitoring plan that deﬁnes adverse events (AEs) and
erious AEs (SAEs), taking into consideration the
tudy design, known and potential risks of the inves-
igational product, the patient population under study,
nd any regulatory or sponsor requirements. SAEs
enerally include any adverse event that causes death
r threat to life, hospitalization, disability, or congen-
tal abnormalities, but even these deﬁnitions are some-
hat open to interpretation, and pertinent details
hould be included in the protocol. The protocol
hould also specify the requirements for reporting
Es. In general, investigators are expected to provide
xpedited reports of SAEs to sponsors within 24 hours
8], and sponsors are expected to provide expedited
eports to the US Food and Drug Administration
FDA) if there are any unexpected SAEs. Investigators
nd sponsors are required to report to the institutional
eview board any unanticipated problems involving
isk to human subjects or others.
onsiderations for Multi-institutional Studies
Multi-institutional studies provide faster enroll-
ent and allow wider generalization of results. Pro-
ocols for multi-institutional studies should address
tandardization of routine management strategies,
onitoring, and endpoint assessment, because differ-
nces in management can confound the assessment of
atient-reported outcomes and quality of life. Audits
nd centralized training of individuals who assess
atients, follow protocol-mandated procedures, exam-
ne histopathology, perform chronic GVHD grading,
nd assess clinical trial endpoints may improve com- s
B&MTliance and reproducibility. Likewise, centralized re-
iew of histopathology, clinical grading, and response
ssessments may improve reproducibility and unifor-
ity across institutions. These quality enhancements
dd greatly to the costs of conducting clinical trials.
RIMARY AND SECONDARY ENDPOINTS
election of Endpoints
The choice of speciﬁc primary and secondary end-
oints will be inﬂuenced by the nature and scope of
laims to be made at the end of the study, the type of
ntervention, study phase, indication (prevention, pri-
ary treatment or secondary treatment), conduct in
n academic versus community setting, and by the
resence or absence of blinding. Potential primary
nd secondary endpoints that could be used in chronic
VHD studies are listed in Table 1. These include
hysician-assessed response (complete response, par-
ial response, stable disease or no response, progres-
ion), patient-reported outcomes, time to GVHD
rogression, transplant-related mortality, disease-free
urvival, overall survival, survival to resolution of
hronic GVHD, and survival to permanent discontin-
ation of immunosuppressive treatment. The end-
oints in Table 1 are listed in ascending order accord-
ng to the scope of potential conclusions that could be
ade for the indication(s) of the product under study.
VHD response and patient-reported outcomes
ould be applied globally or to speciﬁc organs, de-
ending on the nature of the intervention and the
rgans or sites affected by the disease.
Valid primary and secondary endpoints of chronic
VHD treatment studies should focus on the clinical
eneﬁts of central importance to patients: survival free
f the underlying disease, freedom from chronic
VHD manifestations, treatment and complications,
nd improvement in symptoms, function, and quality
f life. Intermediate endpoints that reﬂect the degree
f chronic GVHD activity, such as physician assess-
ent, biochemical tests, and biomarkers, are impor-
ant only to the extent that they may predict or con-
rm 1 of the patient-experienced outcomes [9,10].
ecause chronic GVHD typically has a prolonged
linical course, extended follow-up is strongly encour-
ged to ensure that responses are durable. The mini-
um duration of response required to designate treat-
ent as “successful” will vary according to trial design
nd endpoint. Requirements for durability of re-
ponse should be prespeciﬁed in the deﬁnition of
ndpoints. Where applicable, criteria for failure of
rimary therapy and failure of secondary treat-
ent should be deﬁned.
Complete response, strictly deﬁned partial re-
ponse, and validated early surrogate markers of
uccess or failure are highly appropriate endpoints
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4or phase II studies. Results for these endpoints can be
ssessed within the ﬁrst several months after enroll-
ent and are not greatly affected by subsequent man-
gement or other competing late events such as recur-
ent malignancy. Outcomes with wider scope such as
ermanent resolution of chronic GVHD or survival
re highly appropriate endpoints for phase III studies,
ut statistical methods must account for concomitant
reatment and competing events such as death or
ecurrent malignancy during immunosuppressive
reatment. Chronic GVHD may decrease the risk of
ecurrent malignancy and increase the risk of death
rom causes other than recurrent malignancy. Hence,
ssessment of overall beneﬁt must account for trade-
ffs between the 2 by using composite endpoints in
able 1. Potential Primary and Secondary Endpoints for Chronic GVH
Endpoint* Interpretation
VHD response Response to treatment accor
organ-specific or summary
measurements
atient-reported outcomes Self-assessed morbidity cause
chronic GVHD or treatmen
ransplant-related mortality Death before recurrence or
progression of malignancy
elapse-free survival Survival without recurrent m
verall survival Survival
elapse-free survival to
resolution of GVHD†
Complete response
elapse-free survival to
permanent
discontinuation of
immunosuppressive
treatment†
Cure
Endpoint probabilities can be estimated as cumulative incidence or
follow-up. Cumulative incidence estimates can be inﬂuenced b
estimated and compared by Cox regression.
Secondary treatment is considered to be an indication of failure.hich death or recurrent malignancy is considered as s
98reatment failure. Stratiﬁcation can be used to ensure
hat competing risks are balanced between arms.
esponse Criteria
The dimensions of response measurement should
e deﬁned, including the organ systems and sites in-
olved by chronic GVHD, types of manifestations,
nd extent of involvement. The development and ap-
lication of response criteria for chronic GVHD pose
ery difﬁcult challenges, especially in phase II studies
n which the proportion of subjects with complete
esponses may be low [6]. If possible, active, reversible
isease manifestations should be distinguished from
xed deﬁcits and irreversible damage. Overall re-
tment Trials
Time to
Endpoint Biostatistical Notes
Short Scales for measurement of response
have not yet been validated. Results
may be affected by changes in
ancillary treatment and supportive
care. Endpoint is subject to bias and
has greater validity in blinded trials.
Most appropriate as a primary
endpoint in phase II studies and
possibly in selected phase III studies.
Short Missing data and informative censoring
are major problems. Few sensitive
instruments are available. Results
may be affected by changes in
ancillary treatment and supportive
care. Endpoint is subject to bias and
has greater validity in blinded trials.
Best used as a secondary endpoint.
Long Endpoint measures failure rather than
success. Also known as chronic
GVHD-specific mortality in the
literature. Best used as a secondary
endpoint.
cy Long Objective endpoint, but not specific to
chronic GVHD. Best used as a
secondary endpoint.
Long Objective endpoint, ultimate gold
standard, but may not be specific to
chronic GVHD. Best used as a
secondary endpoint.
Long Endpoint must account for continued
immunosuppressive treatment. Best
used as a primary endpoint in phase
III studies.
Long Best used as a primary endpoint in
phase III studies.
ortions of success or failure at a speciﬁed time point with complete
requency of competing risks. Endpoint rates (ie, hazards) can beD Trea
ding to
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t
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Design of Clinical Trials in Chronic GVHD
Bccepted measurements of disease activity in each or-
an or site. Concomitant therapy must be controlled
hen response is the primary endpoint of phase II
tudies designed to assess the efﬁcacy of an investiga-
ional agent. The timing of response assessment
hould be deﬁned (eg, 6 weeks or 3-6 months from
nrollment), and results should indicate whether re-
ponses were durable after completion of treatment.
hen resources are available, clinical impressions can
e validated through assessment by several individuals
nd by subspecialty experts, especially in open-label
tudies. Care should be taken to deﬁne and place a
igher priority on clinically meaningful beneﬁts in the
eﬁnition of endpoints.
upporting Information from Physician and
atient Participants
Physician behavior and patient self-reports can
rovide additional information about responses. For
hysicians, changes in the dose of immunosuppressive
edications and addition of new medications likely
eﬂect the clinical impression of response. Patients
an be queried about quality-of-life or symptom
cales, and they can report changes in performance
nd function with the use of standardized question-
aires. Physician behavior and “patient-reported out-
omes” may be more sensitive to subtle differences in
isease activity, but each involves subjective assess-
ents with uncertain reliability and probable suscep-
ibility to bias, especially in open-label studies. In
linded trials, however, these assessments may be used
o support other more objective response criteria.
IOSTATISTICAL CONSIDERATIONS
revention Trials
In some situations, a clinical trial may be designed
o prevent severe chronic GVHD, eg, through alter-
tions in the nature or source of the graft. Because of
ompeting risks (eg, death and recurrent malignancy
efore the onset of chronic GVHD), cumulative in-
idence estimates, rather than Kaplan-Meier meth-
ds, should be used to evaluate the proportion of
atients who develop chronic GVHD, and the trial
rms should be balanced for competing risks.
Patients can develop chronic GVHD only if they
re engrafted with donor cells and survive for some
inimal time, usually 80-100 days, after HCT. For
hronic GVHD prevention trials, the incidence of
hronic GVHD should be reported as a cumulative
ncidence curve from the inception of the intervention
o prevent the disease, which may vary according to
he design of the study. Death without previous
hronic GVHD should be treated as a competing risk.
ecreasing donor chimerism and recurrence or pro-
ression of an underlying malignancy may inﬂuence i
B&MThe speed with which immunosuppressive medications
re withdrawn and thus indirectly affect onset of
hronic GVHD. Protocols for prevention trials
hould specify whether these events will be treated as
ompeting risks, and justiﬁcation for this decision
hould be provided. The power calculation for pre-
ention trials should specify the minimum clinically
ignificant risk reduction that the study is designed
o detect. The power calculation should also account
or dropouts.
reatment Trials
Primary and secondary endpoints in chronic
VHD treatment trials require careful statistical con-
ideration, as summarized in Table 1. In all cases,
ndpoints, timing of assessments, and statistical meth-
ds should be prespeciﬁed. Kaplan-Meier estimates
an be used to evaluate survival, and cumulative inci-
ence estimates can be considered for evaluation of
ther simple and composite endpoints, depending on
ype of treatment and length of follow-up. All trials
hould be adequately powered to evaluate a prespeci-
ed statistical hypothesis regarding the primary end-
oint, and the statistical hypothesis should address a
linically meaningful beneﬁt. Late-phase studies
hould have data and safety monitoring boards, par-
icularly if they involve multiple institutions. Sched-
led interim analyses may be necessary to evaluate not
nly efﬁcacy but also toxicity and futility, as illustrated
y 3 trials that tested the use of thalidomide to prevent
r treat chronic GVHD [11-13]. Data and safety mon-
toring boards may be appropriate for phase II studies
esting agents with weakly characterized safety proﬁles
hat might jeopardize the safety of subjects and for
tudies that involve particularly vulnerable popula-
ions such as children.
dditional Considerations in Phase II Treatment
rials
For a variety of reasons, results of phase II studies
emain difﬁcult to interpret. Disease characteristics at
he time of enrollment can inﬂuence the chance of
artial or complete response, and the management of
lucocorticoid doses and other concomitant treatment
an have marked effects on short-term outcomes. In
pen-label studies, evaluation of many endpoints is
ighly susceptible to bias. In the absence of well-
eﬁned response criteria, judgments regarding attain-
ent of complete response are likely to be much more
obust than are those regarding partial response.
owever, the short duration of phase II studies and
resence of ﬁxed, irreversible deﬁcits may limit the
umber of patients who have a complete response.
onetheless, phase II studies are useful for screening
reatment options and planning future phase III stud-
es.
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5Changes in treatment must be taken into account
ven when prespeciﬁed objective criteria are used to
easure changes in manifestations of chronic GVHD.
he conduct and interpretation of clinical trials for
reatment of chronic GVHD would be greatly en-
anced by development of biostatistical methods that
ould account for baseline prognostic characteristics
nd for changes in the severity of disease manifesta-
ions and the overall intensity of immunosuppressive
reatment. Crossover designs may be biostatistically
obust if failure is required before patients cross over
in reality, these are extended access trials) or if treat-
ent remains blinded before and after crossover.
onversely, crossover designs can confound the as-
essment of longer-term outcomes such as survival
nd cannot be used with add-on study designs.
dditional Considerations in Phase III Treatment
rials
Although the prespeciﬁed primary endpoint is of
aramount importance in assessing the results of a
hase III clinical trial, other considerations must be
aken into account before reaching an overall conclu-
ion. For example, a secondary analysis of the primary
ndpoint should demonstrate that a favorable differ-
nce in outcome does not reﬂect imbalance in the
istribution of baseline risk factors among arms of the
tudy. Large imbalances for risk factors that might
ffect outcome can be prevented by appropriate strat-
fication for balance. In trials that enroll a large
umber of subjects, stratiﬁcation is generally not nec-
ssary because the likelihood of a signiﬁcant imbal-
nce in risk factors between arms is low. The risk of an
mbalance is higher in trials that enroll smaller num-
ers of subjects, but with limited enrollment, the trial
esign cannot accommodate strata for all of the many
isk factors that are known to affect outcome among
atients with chronic GVHD. Techniques for biased
daptive randomization can be used to prevent an
mbalance in the distribution of multiple risk factors
etween arms. Because imbalances cannot be evalu-
ted after the fact, and because predictive outcomes
ust be based on prespeciﬁed model assumptions,
iased adaptive randomization is not recommended in
linical trials designed for regulatory approval.
In chronic GVHD trials, differences in doses of
ystemic immunosuppressive medications or adminis-
ration of topical therapy among study arms could
ffect the primary endpoint. An effective treatment for
hronic GVHD would be expected to decrease the
verall level of systemic immunosuppression and the
mount of topical therapy. If this is not the case, then
secondary analysis should be carried out to correct
or possible confounding effects of ancillary treatment
nd supportive care on the primary endpoint. Favor-
ble results for the primary endpoint should be sup-
orted by favorable or neutral results for secondary e
00fﬁcacy endpoints and by the absence of side effects
hat outweigh the beneﬁts demonstrated by the efﬁ-
acy endpoints.
andling of Missing Data
Missing data hamper the evaluation of patient-
eported outcomes and other endpoints. Imputation
as been used as a technique to deal with missing data
or patient-reported outcomes, although the use of
his technique should be discussed with the FDA be-
ore being submitted for regulatory review for poten-
ial licensing. Missing data can also affect the assess-
ent of response when the study arms have different
ropout rates, resulting in informative censoring. Pro-
ocols should specify how missing data are be treated,
nd sample size estimates should make allowances for
ropout and informative censoring, when necessary.
ensitivity testing under worst-case assumptions for
issing data can be used to ensure robust results.
EGULATORY REVIEW
Additional considerations of clinical trial design,
ndpoint choice, and study conduct are required of
rials intended for licensing review by the FDA. These
onsiderations include, but are not limited to, require-
ents for the use of validated measurements as pri-
ary endpoints, study designs that incorporate ap-
ropriate controls, and, whenever possible, blinding
f study intervention and endpoint assessment to en-
ure the absence of bias. Sponsors and investigators
hould consider requesting a Special Protocol Assess-
ent from the FDA before beginning a clinical trial
ntended to support a licensing application [14].
FDA can approve a new drug application or a new
ndication only after determining that the drug meets
he statutory standards for safety and effectiveness,
mong other requirements. The FDA may refuse to
pprove an application if there is insufﬁcient informa-
ion about a drug to determine whether it is safe for
se under the conditions prescribed or if there is a lack
f substantial evidence that the drug will have its
urported effect under the conditions of use pre-
cribed, among other reasons.
ssessment of Safety
Clinical trials intended for regulatory review must
eet rigorous standards of design and conduct. In all
linical trials, assessment of safety through timely
valuation and reporting of all serious adverse events
equires close attention. Regulatory requirements for
eporting of adverse events should be followed. Clin-
cal trial protocols should have guidelines that require
etailed evaluation of adverse events that are not se-
ious and expedited reporting of serious adverse
vents to the principal investigator and sponsor. Ex-
p
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Design of Clinical Trials in Chronic GVHD
Bedited reporting to FDA is required for unexpected
erious adverse events.
ssessment of Efficacy
Regulatory approval requires persuasive evidence
f efﬁcacy. Assessment of efﬁcacy involves the mea-
urement of an outcome variable that reﬂects clinical
eneﬁt and an evaluation of the statistical robustness
nd reproducibility of the trial results. Endpoints
hould be selected to provide evidence of meaningful
linical beneﬁt for patients. Tools and instruments
sed to capture endpoint information must be well
haracterized and validated. Clear deﬁnitions of fail-
re and success must be provided.
Endpoints of limited scope and subjective end-
oints that are not supported by objective measure-
ents may be highly appropriate for the assessment of
ome interventions. For example, stabilization of pul-
onary function tests might be appropriate in the
valuation of an inhalational agent for treatment of
ronchiolitis obliterans in patients who previously
howed consistent deterioration before enrollment in
he study. Validated surrogate endpoints that have
een demonstrated to indicate clinical beneﬁt could
erve as endpoints for phase II studies, although no
uch surrogate endpoints have yet been identiﬁed or
alidated for patients with chronic GVHD. Secondary
fﬁcacy endpoints in phase II studies can include the
urvival-related endpoints of wider scope that could be
sed as primary efﬁcacy endpoints in phase III studies.
f the study populations are similar, information from
he secondary endpoints of earlier phase studies can be
sed to inform the estimates of effect size needed to
esign phase III studies that have primary endpoints
f wider scope related to longer-term survival.
esign of Phase III Clinical Trials
The FDA has summarized the characteristics of
dequate and well-controlled “pivotal” studies needed
or regulatory approval in the United States [15].
hese characteristics include (1) a clear statement of
he objectives and methods of analysis, with an im-
licit emphasis on prospective design, (2) a valid com-
arison with a control to provide a quantitative assess-
ent of effect, (3) a method of selection of subjects
hat provides adequate assurance that they have the
isease being studied, (4) a method to avoid bias in the
ssignment of subjects to treatment and controls
roups, (5) adequate measures to minimize bias on the
art of subjects, observers, and analysts of the data, (6)
ell-deﬁned and reliable methods to assess subjects’
esponses, and (7) an analysis that is adequate to assess
he effects of the treatment. a
B&MTHALLENGES FOR THE FUTURE
Improvements in clinical trial design can facili-
ate advances in the treatment of chronic GVHD
nly if drugs or devices previously approved for
ther indications or new therapeutic agents cur-
ently under development have activity against
hysiologic pathways leading to development or
rogression of the disease. Current understanding
f the pathophysiology leading to chronic GVHD is
imited, but deeper insight could come from non-
linical models and studies of other diseases that
esult in similar clinical manifestations, such as
cleroderma and Sjögren syndrome. A more sophis-
icated understanding of the pathogenesis of
hronic GVHD, combined with the availability of
gents directed at speciﬁc targets in pathways lead-
ng to development of the disease, could lead to
mprovements in outcomes for patients after allo-
eneic HCT.
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5PPENDIX
onsensus Definitions and Glossary—2006
ppropriate controls: A comparison group (usually
istorical or concurrent) that provides information
bout the likely course of chronic GVHD without the
ntervention under study.
iased adaptive randomization: A biostatistical
ethod of randomization that allows preferential as-
ignment of subjects in a manner that balances the
istribution of speciﬁed risk factors between study
rms.
entralized training: A method to ensure valid and
eliable (intra- and inter-rater) assessment of histopa-
hology, chronic GVHD grading, and clinical trial
ndpoints; may include initial and ongoing training,
ssessment and feedback, and repeated assessments to
heck for intra-rater reliability.
linically meaningful differences: A measurement
f whether effect size (differences between popula-
ions or between baseline and subsequent evaluations)
as clinical and statistical signiﬁcance. Two methods
re available to establish clinically meaningful differ-
nces: methods derived from an estimate of minimum
mportant differences based on the distribution of
easurements in a population and methods derived
rom measured changes anchored on patient percep-
ion, clinician perception, or behavioral elements.
ompeting events: Events that preclude or modify
he risk of the outcome of interest. For example, death
s generally considered a competing event for most
ndpoints, including chronic GVHD, because death
recludes subsequent assessment of other outcomes.
imilarly, progression or relapse of the underlying
isease may be considered as a competing risk for
VHD because therapeutic interventions for treat-
ent of the disease may modify the risk of GVHD.
riteria for secondary treatment: Failure of primary
herapy as indicated by progression of chronic GVHD
anifestations despite optimal ﬁrst line therapy, eg, with
rednisone at doses 1.0 mg · kg1 · d1 for 2 weeks;
lternatively, administration of secondary therapy when
rimary therapy results in stable persistence of
hronic GVHD manifestations and lack of improve-
ent despite 4-8 weeks of sustained therapy, eg, with
rednisone at doses .5 mg · kg1 · d1 or an inabil-
ty to taper prednisone doses to .5 mg · kg1 · d1
ithout recurrence of manifestations. A speciﬁc min-
mum duration of primary therapy should be deﬁned
or enrollment in clinical trials of secondary therapy.
arly initiation of secondary therapy would be appro-
riate in patients with more severe chronic GVHD,
hereas a longer trial of initial therapy would be
ppropriate in patients with sclerotic skin changes or
ther slowly reversible manifestations of chronic
VHD. A longer duration of primary therapy wouldlso be appropriate when the agent to be used or c
02valuated for secondary therapy has a high risk of
oxicity. Depending on the study design, inability to
olerate primary therapy or lack of a satisfactory re-
ponse to initial therapy may be considered an indi-
ation for secondary treatment or for enrollment in a
linical trial to evaluate secondary treatment.
riteria for treatment of newly diagnosed chronic
VHD: Oral, ocular, and cutaneous manifestations
epresent the most frequent and sensitive indicators of
hronic GVHD. Systemic treatment is always indi-
ated when multiple sites are involved. Likewise, sys-
emic immunosuppressive therapy is indicated for pa-
ients with a quiescent or progressive onset who are
iagnosed with chronic GVHD during treatment with
rednisone, because GVHD manifestations in these
atients would almost certainly have greater severity
n the absence of steroid administration. In this case,
reatment of chronic GVHD would require adminis-
ration of steroids at a higher dose or the addition of
nother immunosuppressive medication [3]. Systemic
mmunosuppressive therapy should be considered for
atients with chronic GVHD and thrombocytopenia
platelet count 100 000/L) or other ﬁndings or
iomarkers associated with an increased risk of non-
elapse mortality [16].
umulative incidence: A measurement of the actual
ate of an outcome of interest in the study population,
hich accounts for any competing events. Subjects
ith uninformative outcomes (eg, death before onset
f chronic GVHD) are included in cumulative inci-
ence calculations but are censored (removed from
he denominator) in Kaplan-Meier calculations. The
aplan-Meier method assumes that patients who are
ensored because of competing events are at the same
isk of an outcome of interest as are patients who have
ot been censored. This assumption may not hold
rue. When competing events occur in some patients
efore outcomes of interest in others, estimates gen-
rated according to the Kaplan-Meier method are
igher than those generated using the cumulative in-
idence methods, leading to an overestimation of the
utcome of interest. Both methods censor follow-up
or surviving patients at the date of last contact.
isease activity: Evidence of active chronic GVHD
hat may respond to appropriate treatment aimed at
ontrolling pathologic processes causing chronic
VHD, as distinguished from complications of ther-
py, comorbid conditions, or ﬁxed irreversible defects
hat will not resolve even if pathologic processes that
ause chronic GVHD are controlled.
ata and safety monitoring board: An independent
roup of experts who review the conduct and selected
utcomes such as safety, efﬁcacy, or futility (including
ate of accrual) during clinical trials.
arly surrogate markers of success or failure:Mea-
urements (including laboratory, physiologic testing,
linical measurements, or biomarkers) validated to
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Design of Clinical Trials in Chronic GVHD
Bredict later clinical outcomes of importance. The
urrogate marker must be adequately sensitive and
peciﬁc for later clinical events so that they can sub-
titute for longer-term outcomes.
ailure: As applied to evaluation of efﬁcacy, failure of
herapy to control chronic GVHD, eg, progression of
hronic GVHD or addition of new systemic immuno-
uppressive therapy, because of judgments that mani-
estations of chronic GVHD are not adequately con-
rolled.
ailure of primary therapy: This will usually include
ny of the following events during primary therapy:
ecurrent malignancy or death, inability to tolerate
tudy treatment, progression of chronic GVHD, or
ddition of new systemic immunosuppressive therapy
rompted by inadequately controlled chronic GVHD
anifestations. An exacerbation of chronic GVHD
anifestations during withdrawal of treatment is gen-
rally not considered primary treatment failure unless
anifestations exceed those at the beginning of the
rial or do not improve after reinstatement of previous
reatment. Stable disease without new systemic immu-
osuppressive therapy is not considered primary treat-
ent failure.
ailure of secondary treatment: This is indicated by
rogression of chronic GVHD manifestations despite
econd-line therapy; alternatively, administration of
ertiary therapy when secondary therapy results in
table persistence of active chronic GVHD manifes-
ations and lack of improvement despite 4 weeks of
herapy. The protocol should specify how recurrent
alignancy or death, inability to tolerate secondary
herapy, and ﬂare of chronic GVHD manifestations
uring taper of secondary therapy will be interpreted
or endpoint assessment.
ixed, irreversible deficits (“damage”):Organ man-
festations that will not resolve even with adequate
reatment of chronic GVHD. Some such deﬁcits may
mprove with time or with other, non-chronic GVHD
irected therapy, but the period for any possible im-
rovement is longer than the period of follow-up for
clinical trial.
unctional assessments: Self-reported or actual
easurements of ability to perform tasks.
uidelines for tapering of glucocorticoid doses:
apering of steroids should begin soon after the ﬁrst
vidence of improvement in manifestations of chronic
VHD, even if manifestations have not entirely re-
olved. Tapering should be carried out with the goals
f lowering the dose and converting daily glucocorti-
oid administration to an every-other-day regimen
17,18] that can be tolerated for long periods and
revent any exacerbation in manifestations of chronic
VHD. Administration of glucocorticoids should
hen continue at stable doses until all reversible man-
festations of chronic GVHD resolve. The taper
chedule should be resumed after resolution of all t
B&MTeversible manifestations of GVHD. At the end of the
aper schedule, physicians and patients must be vigi-
ant for recurrent GVHD and symptomatic adrenal
nsufﬁciency, which may require adjustment of glu-
ocorticoid doses. Accelerated tapering of glucocorti-
oid doses may be necessary in patients who have
lucocorticoid-related toxicity, but the beneﬁt of de-
reased toxicity must be weighed against the risk of
ncreased severity of GVHD.
mputation: A statistical technique using prespeciﬁed
ules to ﬁll in missing values when data are incom-
lete.
nability of the patient to tolerate the study inter-
ention: Cessation of the study intervention for any
edical reason (toxicity or side effects) or patient
reference not related to whether or not the study
edication is effective.
evel I data: Basic data collected for all patients
hether or not they are enrolled in chronic GVHD-
argeted trials (eg, demographic characteristics of the
tudy population, survival, recurrent malignancy, date
f last contact).
evel II data: More detailed data collected for pa-
ients who are involved in studies in which the occur-
ence of chronic GVHD is a primary or secondary
ndpoint (eg, baseline treatment variables in studies to
easure the incidence of chronic GVHD or overall
everity of chronic GVHD) or in studies of outcome
mong patients with chronic GVHD (eg, predictors of
rognosis at diagnosis, risk factors, organ-speciﬁc se-
erity, dose of immunosuppressive medications).
evel III data: Very detailed data collected for pa-
ients who are involved in studies to evaluate treat-
ent of chronic GVHD (eg, clinical information to
upport assessment of adverse events and response,
etails of medical management).
inimum clinically significant risk reduction:
inimum decrease in risk that would warrant use of a
reventive strategy.
ewly diagnosed chronic GVHD: Initial onset of
anifestations that are diagnostic of chronic GVHD
3]. Decisions regarding treatment require additional
onsiderations such as the presence or absence of
ymptoms and risk factors for mortality or progression
f the disease.
rgan or site-specific therapies: Treatments de-
igned primarily to affect a speciﬁc organ manifesta-
ion or site of chronic GVHD. The term ancillary
reatment refers to interventions directed toward con-
rolling immune responses or inﬂammation at a spe-
iﬁc site. The term supportive care refers to other
nterventions that are not directed toward immune
esponses or inﬂammation.
verlap syndromes: An increasingly recognized syn-
rome of chronic GVHD in which manifestations
ypical of acute GVHD are present [3].
503
“
t
Q
t
s
a
R
p
p
R
d
l
D
t
o
f
S
m
“
m
s
a
i
S
t
r
e
S
e
e
e
o
l
S
t
t
s
S
s
o
S
m
i
e
T
w
a
U
i
a
V
c
o
p
e
c
r
N
C
S
c
L
S
e
S
r
M
P
R
n
ﬁ
s
d
t
d
c
R
P. J. Martin et al
5Primary” therapy: First systemic intervention in-
ended speciﬁcally to treat chronic GVHD.
uality of life: A multidimensional (physical, func-
ional, emotional, social, spiritual) self-reported as-
essment that in sum indicates satisfaction with life
nd overall sense of well-being.
ecurrent or progressive malignancy: Recurrent (if
reviously in remission) or progressive (if previously
ersistent after HCT) malignancy.
equirements for durability of response: This will
epend on the phase of the trial and will likely be
onger for phase III studies than for phase II studies.
urability of response is deﬁned as the minimum period
hat improvement must last, from the time it is ﬁrst
bserved to the time that it is accepted as a response
or purposes of deﬁning outcome in a clinical trial.
econdary treatment: Any systemic treatment ad-
inistered because of efﬁcacy failure.
Standard” steroid therapy: Prednisone at 1
g · kg1 · d1 or equipotent doses of other cortico-
teroids, initially administered once daily and gener-
lly followed by conversion to an every-other-day reg-
men.
teroid-dependent: Controlled or absent manifesta-
ions of chronic GVHD during administration of ste-
oid therapy, with exacerbation or recurrence when-
ver steroid doses are tapered.
teroid-intolerant: Intolerance of steroid doses nec-
ssary to control chronic GVHD. Examples of intol-
rance should be clearly deﬁned in each trial. For
xample, intolerance may be deﬁned as development
f insulin-dependent diabetes or symptomatic avascu-
ar necrosis.
tratification for balance: A method of randomiza-
ion according to speciﬁed subgroups of subjects so
hat important covariates are balanced in the overall
tudy populations to be compared in a clinical trial.
tratiﬁcation for balance can be done with or without
tratiﬁcation in the analysis, depending on the number
f subjects in each stratum.
ystemic immunosuppressive treatment: Any im-
unosuppressive treatment designed to control man-
festations of active chronic GVHD throughout the
ntire body.
opical therapy: Any treatment delivered locally
ith the goal of treating the tissues to which it is
pplied, without signiﬁcant effects at other sites.
ncontrolled infection: Bacterial, viral, or fungal
nfection that is not adequately controlled by current
nti-infective or surgical therapy.
alidated instruments: Methods of measuring out-
omes that are reasonable (face validity) and previ-
usly demonstrated to (1) include all important as-
ects of disease (content validity), (2) perform as
xpected (construct validity), and (3) measure clini-
ally meaningful change (sensitivity) across the full
ange of illness.
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